Inhibrx’s (INBX) Market Perform Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market perform rating on shares of Inhibrx (NASDAQ:INBX) in a research note published on Wednesday,Benzinga reports.

Inhibrx Trading Down 4.2 %

INBX stock opened at $13.60 on Wednesday. The firm has a fifty day moving average price of $14.68 and a two-hundred day moving average price of $14.67. Inhibrx has a 1-year low of $10.80 and a 1-year high of $18.95.

Insiders Place Their Bets

In related news, Director Jon Faiz Kayyem bought 69,686 shares of the stock in a transaction dated Tuesday, November 19th. The stock was bought at an average cost of $14.23 per share, with a total value of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares of the company’s stock, valued at $727,053.39. This trade represents a -374.80 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inhibrx stock. Exchange Traded Concepts LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,608 shares of the company’s stock, valued at approximately $148,000. Exchange Traded Concepts LLC owned about 0.07% of Inhibrx as of its most recent filing with the Securities & Exchange Commission. 82.46% of the stock is owned by hedge funds and other institutional investors.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.